MAXCYTE INC (MXCT) Stock News

USA - NASDAQ:MXCT - US57777K1060 - Common Stock

1.635 USD

-0.01 (-0.91%)

Last: 10/23/2025, 1:10:10 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MXCT Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: MaxCyte, Inc

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

15 days ago - By: MaxCyte, Inc

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

17 days ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

17 days ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

3 months ago - By: The Motley Fool

MaxCyte (MXCT) Q2 Revenue Drops 18%

3 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

a month ago - By: MaxCyte, Inc

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

a month ago - By: MaxCyte, Inc

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

2 months ago - By: Yahoo Finance - Mentions: ACET

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio

6 months ago - By: Benzinga - Mentions: XPER EMR BLZE ERII ...

Earnings Scheduled For May 7, 2025

3 months ago - By: Zacks Investment Research - Mentions: IOVA

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: MaxCyte, Inc

MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

3 months ago - By: MaxCyte, Inc

MaxCyte Signs Platform License Agreement with Adicet Bio

3 months ago - By: MaxCyte, Inc

MaxCyte Signs Platform License Agreement with Adicet Bio

3 months ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

3 months ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

4 months ago - By: MaxCyte, Inc

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

4 months ago - By: MaxCyte, Inc

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

4 months ago - By: MaxCyte, Inc

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

4 months ago - By: MaxCyte, Inc

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

5 months ago - By: Yahoo Finance - Mentions: DHI CMG

MaxCyte, Inc. (MXCT): A Bull Case Theory

6 months ago - By: Zacks Investment Research - Mentions: CUE

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

6 months ago - By: MaxCyte, Inc

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

7 months ago - By: MaxCyte, Inc

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

7 months ago - By: MaxCyte, Inc

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

8 months ago - By: MaxCyte, Inc

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

8 months ago - By: MaxCyte, Inc

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

8 months ago - By: MaxCyte, Inc

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

9 months ago - By: MaxCyte, Inc

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference